Related Experiment Video
Updated: Sep 23, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
microRNA-324-3p suppresses the aggressive ovarian cancer by targeting WNK2/RAS pathway
Fengjie Li1, Zhen Liang2, Yongqin Jia1
1Department of Obstetrics and Gynecology, Southwest Hospital, Third Military Medical University, Chongqing, Sichuan , China.
Abstract:
Ovarian cancer (OC) has the highest mortality rate among gynecological cancers, which progresses owing to dysregulated microRNAs (miRNAs) expression. Our study attempts to reveal the mechanism by which decreased miR-324-3p expression suppresses OC proliferation. Quantitative real-time PCR, western blotting, in situ hybridization, and immunohistochemistry were performed to estimate miR-324-3p and WNK2 expression levels in OC cells and tissues. Cell Counting Kit-8, colony formation, EdU, and transwell assays were performed to analyze the influence of miR-324-3p and WNK2 on the proliferation and invasion ability of OC cells. Subsequently, xenograft models were established to examine the effects of WNK2 on OC cell proliferation in vivo, and databases and luciferase reporter assays were used to test the relationship between miR-324-3p and WNK2 expression. Then, we showed that miR-324-3p expression is decreased in OC cells and tissues, indicating its inhibitory effect on OC cell proliferation. Quantitative real-time PCR and luciferase reporter assays demonstrated that miR-324-3p inhibited WNK2 expression by directly binding to its 3' untranslated region. WNK2, an upregulated kinase, promotes the proliferation and invasion of OC cells by activating the RAS pathway. Moreover, WNK2 can partly reverse the inhibitory effects of miR-324-3p on OC cell proliferation. Hence, we demonstrate that miR-324-3p suppressed ovarian cancer progression by targeting the WNK2/RAS pathway. Our study provides theoretical evidence for the clinical application potential of miR-324-3p.
Insights
Decreased miR-324-3p suppresses ovarian cancer (OC) by targeting WNK2 kinase and the RAS pathway. This finding offers potential for miR-324-3p as a therapeutic target in OC treatment.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Ovarian cancer (OC) exhibits high mortality due to complex progression mechanisms.
- Dysregulated microRNA (miRNA) expression is implicated in OC development and advancement.
- Identifying specific miRNA roles is crucial for understanding OC pathogenesis.
Purpose of the Study:
- To elucidate the mechanism by which reduced miR-324-3p expression inhibits OC proliferation.
- To investigate the regulatory relationship between miR-324-3p and WNK2 in ovarian cancer.
- To explore the potential of miR-324-3p as a therapeutic target for OC.
Main Methods:
- Quantitative real-time PCR and western blotting to assess miR-324-3p and WNK2 expression.
- Cell proliferation, invasion assays (CCK-8, colony formation, EdU, transwell), and xenograft models for in vivo validation.
- Luciferase reporter assays and bioinformatics to confirm direct targeting of WNK2 by miR-324-3p.
Main Results:
- miR-324-3p expression was significantly decreased in OC cells and tissues.
- miR-324-3p directly targets the 3' untranslated region of WNK2, inhibiting its expression.
- Upregulated WNK2 kinase promotes OC cell proliferation and invasion via the RAS pathway.
- Restoration of WNK2 partially reversed the inhibitory effects of miR-324-3p.
Conclusions:
- miR-324-3p suppresses ovarian cancer progression by targeting the WNK2/RAS pathway.
- The miR-324-3p/WNK2 axis represents a potential therapeutic strategy for ovarian cancer.
- This study provides a mechanistic basis for the clinical application of miR-324-3p in OC.
Related Concept Videos
MicroRNAs
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation

